Molecular Cancer Therapeutics · 2017 · 103 citations · 41 references
MedicineCancer BiologyOncologyCell SignalingInflammationMolecular OncologyApoptosis ResistanceCancer Cell SignalingCancer-associated FibroblastsCytokine BiologyCytokine Receptor SignalingCytokine SignalingCytokine Signaling In CancerCytokine Signaling In TumorsDrug-induced ApoptosisEpithelial-mesenchymal Transition MarkersMolecularly Targeted AgentsNon-small Cell Lung Cancer TreatmentStat3 SignalingTumor-associated Cytokines
Abstract Molecularly targeted drugs have yielded significant therapeutic advances in oncogene-driven non–small cell lung cancer (NSCLC), but a majority of patients eventually develop acquired resistance. Recently, the relation between proinflammatory cytokine IL6 and resistance to targeted drugs has been reported. We investigated the functional contribution of IL6 and the other members of IL6 family proinflammatory cytokine pathway to resistance to targeted drugs in NSCLC cells. In addition, we examined the production of these cytokines by cancer cells and cancer-associated fibroblasts (CAF). We also analyzed the prognostic significance of these molecule expressions in clinical NSCLC samples. In NSCLC cells with acquired resistance to targeted drugs, we observed activation of the IL6–cytokine pathway and STAT3 along with epithelial-to-mesenchymal transition (EMT) features. In particular, IL6 family cytokine oncostatin-M (OSM) induced a switch to the EMT phenotype and protected cells from targeted drug-induced apoptosis in OSM receptors (OSMRs)/JAK1/STAT3–dependent manner. The cross-talk between NSCLC cells and CAFs also preferentially activated the OSM/STAT3 pathway via a paracrine mechanism and decreased sensitivity to targeted drugs. The selective JAK1 inhibitor filgotinib effectively suppressed STAT3 activation and OSMR expression, and cotargeting inhibition of the oncogenic pathway and JAK1 reversed resistance to targeted drugs. In the analysis of clinical samples, OSMR gene expression appeared to be associated with worse prognosis in patients with surgically resected lung adenocarcinoma. Our data suggest that the OSMRs/JAK1/STAT3 axis contributes to resistance to targeted drugs in oncogene-driven NSCLC cells, implying that this pathway could be a therapeutic target. Mol Cancer Ther; 16(10); 2234–45. ©2017 AACR.
41
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman, Teppei Morikawa, Kevin Shee et al. · Nature · 2012 · 1.7K citations · Full text
Medicine, Cancer Biology, Oncology +15
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou et al. · Journal of Clinical Oncology · 2012 · 1.6K citations · Full text
Interleukin-6 family of cytokines and gp130
Tadamitsu Kishimoto, Shizuo Akira, Masashi Narazaki et al. · Blood · 1995 · 1.3K citations · Full text
New driver mutations in non-small-cell lung cancer
William Pao, Nicolas Girard · The Lancet Oncology · 2011 · 1.1K citations
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson, Jane Fridlyand, Yibing Yan et al. · Nature · 2012 · 1.1K citations
Medicine, Cancer Biology, Oncology +16